Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
opioid peripherally acting mu-opioid receptor antagonist |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2014 |
| gptkbp:ATCCode |
A06AH04
|
| gptkbp:brand |
gptkb:Movantik
Moventig |
| gptkbp:CASNumber |
99532-79-9
|
| gptkbp:category |
laxative
opioid withdrawal agent |
| gptkbp:contraindication |
known or suspected gastrointestinal obstruction
|
| gptkbp:developer |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
6-11 hours
|
| gptkbp:hasMolecularFormula |
C34H51NO11
|
| gptkbp:hasSMILES |
CC(C)OC(=O)[C@@H]1CC[C@H]2[C@@]3(CCN4CCC[C@]34O2)[C@H]1O[C@H]5CO[C@H](CO)[C@@H](O)[C@H]5O
|
| https://www.w3.org/2000/01/rdf-schema#label |
naloxegol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
blocks peripheral mu-opioid receptors
|
| gptkbp:metabolism |
gptkb:CYP3A4
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
23667555
28536141 CHEMBL2105752 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain flatulence |
| gptkbp:UNII |
6V9V1KG1LU
|
| gptkbp:usedFor |
opioid-induced constipation
|
| gptkbp:bfsParent |
gptkb:Movantik
|
| gptkbp:bfsLayer |
7
|